EdgarLookup

Sagimet Biosciences Inc. — Quarterly Financials

Quarterly figures from SEC EDGAR XBRL filings (10-Q)

These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Sagimet Biosciences Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.

Overview All Filings Annual Quarterly Insiders

Revenue — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2024 Sep 30, 2023 $2.00M Nov 14, 2024
Q3 2023 Jul 31, 2023 $2.00M Nov 13, 2023

Net Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($12.91M) Nov 13, 2025
Q2 2025 Jun 30, 2025 ($10.39M) Aug 13, 2025
Q3 2025 Jun 30, 2025 ($10.39M) Nov 13, 2025
Q3 2025 Mar 31, 2025 ($18.18M) Nov 13, 2025
Q1 2025 Mar 31, 2025 ($18.18M) May 8, 2025
Q2 2025 Mar 31, 2025 ($18.18M) Aug 13, 2025
Q3 2025 Sep 30, 2024 ($14.62M) Nov 13, 2025
Q3 2025 Jun 30, 2024 ($8.12M) Nov 13, 2025
Q2 2025 Jun 30, 2024 ($8.12M) Aug 13, 2025
Q1 2025 Mar 31, 2024 ($6.63M) May 8, 2025
Q2 2025 Mar 31, 2024 ($6.63M) Aug 13, 2025
Q3 2025 Mar 31, 2024 ($6.63M) Nov 13, 2025
Q3 2024 Sep 30, 2023 ($6.35M) Nov 14, 2024
Q3 2024 Jun 30, 2023 ($6.79M) Nov 14, 2024
Q2 2024 Jun 30, 2023 ($6.79M) Aug 14, 2024
Q2 2024 Mar 31, 2023 ($6.59M) Aug 14, 2024
Q1 2024 Mar 31, 2023 ($6.59M) May 15, 2024
Q3 2024 Mar 31, 2023 ($6.59M) Nov 14, 2024
Q3 2023 Sep 30, 2022 ($7.47M) Nov 13, 2023
Q3 2023 Jun 30, 2022 ($7.10M) Nov 13, 2023

Operating Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($14.33M) Nov 13, 2025
Q2 2025 Jun 30, 2025 ($11.93M) Aug 13, 2025
Q1 2025 Mar 31, 2025 ($19.87M) May 8, 2025
Q3 2025 Sep 30, 2024 ($16.90M) Nov 13, 2025
Q2 2025 Jun 30, 2024 ($10.59M) Aug 13, 2025
Q1 2025 Mar 31, 2024 ($8.77M) May 8, 2025
Q3 2024 Sep 30, 2023 ($7.45M) Nov 14, 2024
Q2 2024 Jun 30, 2023 ($7.06M) Aug 14, 2024
Q1 2024 Mar 31, 2023 ($6.77M) May 15, 2024
Q3 2023 Sep 30, 2022 ($7.69M) Nov 13, 2023
Q2 2023 Jun 30, 2022 ($7.24M) Aug 21, 2023